Distinct dendritic cell subsets differentially regulate the class of immune response<i>in</i><i>vivo</i>

TLDR

Dendritic cells uniquely stimulate T cells to initiate adaptive immunity. Injection of Flt3‑ligand expands both lymphoid‑ and myeloid‑related DCs, whereas PEG‑GM‑CSF expands only myeloid DCs, and these subsets differentially drive Th1 versus Th2 cytokine production and skew ovalbumin‑specific antibody isotypes, with FL inducing a massive IgG2a response and GM‑CSF favoring IgG1, underscoring distinct DC subsets as modulators of immune response type.

Abstract

Dendritic cells (DCs) are unique in their ability to stimulate T cells and initiate adaptive immunity. Injection of mice with the cytokine Flt3-ligand (FL) dramatically expands mature lymphoid and myeloid-related DC subsets. In contrast, injection of a polyethylene glycol-modified form of granulocyte/macrophage colony-stimulating factor (GM-CSF) into mice only expands the myeloid-related DC subset. These DC subsets differ in the cytokine profiles they induce in T cells in vivo. The lymphoid-related subset induces high levels of the Th1 cytokines interferon gamma and interleukin (IL)-2 but little or no Th2 cytokines. In contrast, the myeloid-related subset induces large amounts of the Th2 cytokines IL-4 and IL-10, in addition to interferon gamma and IL-2. FL- or GM-CSF-treated mice injected with soluble ovalbumin display dramatic increases in antigen-specific antibody titers, but the isotype profiles seem critically dependent on the cytokine used. Although FL treatment induces up to a 10, 000-fold increase in ovalbumin-specific IgG2a and a more modest increase in IgG1 titers, GM-CSF treatment favors a predominantly IgG1 response with little increase in IgG2a levels. These data suggest that distinct DC subsets have strikingly different influences on the type of immune response generated in vivo and may thus be targets for pharmacological intervention.